Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?

NCT04695080 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT04695080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04695080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?
Lead sponsor
Queen Mary University of London
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 25, 2021
Completion date
December 31, 2027
Enrollment
204 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced multiple sclerosis, progressive multiple sclerosis